The Patient Signal

In this episode, we delve into recent findings from the American College of Cardiology’s annual meeting, where Johnson & Johnson's Impella heart pump was shown to offer no patient benefit in two major trials. The CHIP-BCIS3 trial indicated no reduction in adverse events during complex heart procedures, while the STEMI-DTU trial found no improvement for heart attack patients without cardiogenic shock. These results suggest a need for more selective use of mechanical circulatory support despite FDA approval for high-risk PCI.

Next, we discuss Caris Life Sciences' completion of the Achieve 1 Study, which confirms the effectiveness of its Caris Detect multi-cancer early detection test. The study highlights the superior sensitivity and specificity of Whole Genome Sequencing, with impressive results across various cancer stages, supporting Caris' comprehensive genomic approach to cancer detection.

Meanwhile, a study published in npj Breast Cancer reveals that genomic testing could help address racial disparities in breast cancer survival rates between Black and white women in the US. By using genomic tests from Agendia, the study found that personalized treatment based on genomic results led to similar outcomes for both groups, emphasizing the need for personalized care beyond traditional clinical markers.

Stan Berteloot is a French-American journalist, marketing strategist, and AI expert based in Princeton, New Jersey. A University of Maryland journalism graduate, he navigates the intersection of storytelling, technology, and culture.

As Head of Strategy and CTO at Nytro Marketing, he pioneered AI-driven content creation, launching the AI in Marketing podcast. He also hosts Back in America, a podcast exploring American identity through in-depth conversations on race, misinformation, and AI ethics.

Start your VoiceStream free trial today!